These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 27170757)

  • 1. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
    Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
    J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction.
    Schmidt S; Fritz JV; Bitzegeio J; Fackler OT; Keppler OT
    mBio; 2011; 2(3):e00036-11. PubMed ID: 21610122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
    Kueck T; Neil SJ
    PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.
    Fritz JV; Tibroni N; Keppler OT; Fackler OT
    Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
    Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
    Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vpu binds directly to tetherin and displaces it from nascent virions.
    McNatt MW; Zang T; Bieniasz PD
    PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
    Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of the Cytoplasmic Determinants of Vpu to the Expansion of Virus-Containing Compartments in HIV-1-Infected Macrophages.
    Leymarie O; Lepont L; Versapuech M; Judith D; Abelanet S; Janvier K; Berlioz-Torrent C
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
    Vigan R; Neil SJ
    J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.
    Dubé M; Roy BB; Guiot-Guillain P; Binette J; Mercier J; Chiasson A; Cohen EA
    PLoS Pathog; 2010 Apr; 6(4):e1000856. PubMed ID: 20386718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.
    Rollason R; Dunstan K; Billcliff PG; Bishop P; Gleeson P; Wise H; Digard P; Banting G
    PLoS One; 2013; 8(9):e75680. PubMed ID: 24086611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of inactive tetherin delGPI mutant inhibits HIV-1 Vpu-mediated antagonism of endogenous tetherin.
    Lv M; Wang J; Zhu Y; Wang X; Zuo T; Liu D; Zhang J; Wu J; Zhang H; Kong W; Yu X
    FEBS Lett; 2013 Jan; 587(1):37-43. PubMed ID: 23201263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1.
    Jia X; Weber E; Tokarev A; Lewinski M; Rizk M; Suarez M; Guatelli J; Xiong Y
    Elife; 2014 Apr; 3():e02362. PubMed ID: 24843023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu.
    Goffinet C; Homann S; Ambiel I; Tibroni N; Rupp D; Keppler OT; Fackler OT
    J Virol; 2010 Apr; 84(8):4089-94. PubMed ID: 20147395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serine Phosphorylation of HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors.
    Kueck T; Foster TL; Weinelt J; Sumner JC; Pickering S; Neil SJ
    PLoS Pathog; 2015 Aug; 11(8):e1005141. PubMed ID: 26317613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
    Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
    Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
    J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
    Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
    PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
    Neil SJ; Zang T; Bieniasz PD
    Nature; 2008 Jan; 451(7177):425-30. PubMed ID: 18200009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells.
    Jolly C; Booth NJ; Neil SJ
    J Virol; 2010 Dec; 84(23):12185-99. PubMed ID: 20861257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.